Psychiatry Research
Volume 136, Issue 1 , Pages 1-6 , 15 July 2005

Substance P in serum and cerebrospinal fluid of depressed patients: No effect of antidepressant treatment

  • Michael Deuschle

      Affiliations

    • Central Institute of Mental Health Mannheim, University of Heidelberg, J 5, 68159 Mannheim, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 621 1703 2321; fax: +49 621 1703 2325.
    • ,
  • Peter Sander

      Affiliations

    • Central Institute of Mental Health Mannheim, University of Heidelberg, J 5, 68159 Mannheim, Germany
    • ,
  • Inga Herpfer

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Freiburg Medical School, Hauptstr. 5, 79104 Freiburg, Germany
    • ,
  • Bernd L. Fiebich

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Freiburg Medical School, Hauptstr. 5, 79104 Freiburg, Germany
    • ,
  • Isabella Heuser

      Affiliations

    • Central Institute of Mental Health Mannheim, University of Heidelberg, J 5, 68159 Mannheim, Germany
    • Department of Psychiatry and Psychotherapy, Charité University Hospital, Campus Benjamin Franklin, Eschenallee 3, 14050 Berlin, Germany
    • ,
  • Klaus Lieb

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Freiburg Medical School, Hauptstr. 5, 79104 Freiburg, Germany

Received 7 January 2004 ,Revised 8 November 2004 ,Accepted 18 December 2004.

References 

  1. Berrettini WH, Rubinow DR, Nurnberger JI, Simmons-Alling S, Post RM, Gershon ES. CSF substance P immunoreactivity in affective disorders. Biological Psychiatry. 1985;20:965–970
  2. Bondy B, Baghai TC, Minov C, Schule C, Schwarz MJ, Zwanzger P, et al. Substance P serum levels are increased in major depression: preliminary results. Biological Psychiatry. 2003;53:538–542
  3. Deuschle M, Hamann B, Meichel C, Krumm B, Lederbogen F, Kniest A, et al. Antidepressive treatment with amitriptyline or paroxetine: effects on saliva cortisol concentrations. Journal of Clinical Psychopharmacology. 2003;23:105–201
  4. Freed AL, Audus KL, Lunte SM. Investigation of substance P transport across the blood–brain barrier. Peptides. 2002;23:157–165
  5. Guyenet PG, Aghajanian GK. Excitation of neurons in the nucleus locus coeruleus by substance P and related peptides. Brain Research. 1977;136:178–184
  6. Haddjeri N, Blier P. Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission. Biological Psychiatry. 2001;50:191–199
  7. Hahn MK, Bannon MJ. Stress-induced C-fos expression in the rat locus coeruleus is dependent on neurokinin 1 receptor activation. Neuroscience. 1999;94:1183–1188
  8. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 1960;23:56–62
  9. Herpfer I, Lieb K. Substance P and substance P receptor antagonists in the pathogenesis and treatment of affective disorders. World Journal of Biological Psychiatry. 2003;4:56–63
  10. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998;281:1640–1645
  11. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology. 2004;29:385–392
  12. Landgraf R, Klauschenz E, Bienert M, Ermisch A, Oehme P. Some observations indicating a low brain uptake of [3H]Nle11-Substance P. Pharmazie. 1983;38:108–110
  13. Lieb K, Ahlvers K, Dancker K, Strohbusch S, Reincke M, Feige B, et al. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology. 2002;27:1041–1049
  14. Lieb K, Walden J, Grunze H, Fiebich BL, Berger M, Normann C. Serum levels of substance P and response to antidepressant pharmacotherapy. Pharmacopsychiatry. 2004;37:238–239
  15. Martensson B, Nyberg S, Toresson G, Brodin E, Bertilsson L. Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid. Acta Psychiatrica Scandinavica. 1989;79:586–596
  16. McGregor GP, Bloom SR. Radioimmunoassay of substance P and its stability in tissue. Life Sciences. 1983;32:655–662
  17. McGregor GP, Conlon JM. Regulatory peptide and serotonin content and brush-border enzyme activity in the rat gastrointestinal tract following neonatal treatment with capsaicin; lack of effect on epithelial markers. Regulatory Peptides. 1991;32:109–120
  18. Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiology Reviews. 1993;73:229–308
  19. Rimon R, Le Greves P, Nyberg F, Heikkila L, Salmela L, Terenius L. Elevation of substance P-like peptides in the CSF of psychiatric patients. Biological Psychiatry. 1984;19:509–516
  20. Rupniak NM, Kramer MS. Discovery of the antidepressant and antiemetic efficacy of substance P receptor (NK 1) antagonists. Trends in Pharmacological Sciences. 1999;20:485–490
  21. Sergeyev V, Hokfelt T, Hurd Y. Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. NeuroReport. 1999;10:3967–3970
  22. Shirayama Y, Mitsushio H, Takashima M, Ichikawa H, Takahashi K. Reduction of substance P after chronic antidepressant treatment in the striatum, substantia nigra and amygdala of the rat. Brain Research. 1996;739:70–78
  23. Stout SC, Owens MJ, Nemeroff CB. Neurokinin1 receptor antagonists as potential antidepressants. Annual Review of Pharmacology and Toxicology. 2001;41:877–906

PII: S0165-1781(05)00138-1

doi: 10.1016/j.psychres.2004.12.007

Psychiatry Research
Volume 136, Issue 1 , Pages 1-6 , 15 July 2005

Article Tools

* Image Usage & Resolution